|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation.
|
26265449 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
According to our experimental results, the panel including cf-DNA, SLC5A8 and SLC26A4 hypermethylation, and BRAF(V600E) analysis appears easy, reproducible, and non-invasive for the diagnosis on TC.
|
23931930 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we investigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specific expression of oncogenic BRAF and loss of Pten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).
|
26818109 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, this study on a large cohort of TC patients from Middle East demonstrates that TERT promoter mutations are relatively common, especially in the non-CPTC, and are associated with more aggressive histopathological features, BRAF(V600E) mutation, and disease persistence/recurrence than the WT TERT.
|
26354077 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results reveal a novel (V600E)BRAF-induced mechanism in thyroid tumours progression and provides a rationale for using the PLX4720 inhibitor to target (V600E)BRAF signalling to effectively control progression of thyroid cancer.
|
23435375 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The inability of MEK and RAF inhibitors, U0126 and sorafenib, respectively, to block the mitochondrial localization of BRAF(V600E) has additional therapeutic implications for BRAF(V600E)-positive thyroid cancers.
|
20926530 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this study was to determine whether combined detection of BRAF(V600E) mutation and methylation markers on FNABs could improve the diagnostic accuracy of thyroid cancer.
|
24588959 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma.
|
23414134 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA.
|
29868707 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Second, homogeneous staining occurs in the vast majority of cases, demonstrating that the BRAF(T1799A) mutation is a clonal event in thyroid cancer.
|
23775351 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl.
|
26584635 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for th</span>yroid cancer</span> if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, our results suggest that the mTOR pathway could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the BRAF(V600E) mutation.
|
22549934 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patients in Indian subcontinental population.
|
22105775 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this article, we review the pathogenesis of PTC, and the clinical implications of BRAF(V600E) mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancers.
|
20230995 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation analysis, indicating that the screening for BRAF mutation in FNAB samples has a relevant diagnostic potential.
|
22535974 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving histone deacetylation at critical regulatory regions of the NIS promoter but also provide further support for our previously proposed combination therapy targeting major signaling pathways and histone deacetylase to restore thyroid gene expression for radioiodine treatment of thyroid cancer.
|
24243688 |
2014 |